ライフサイエンスコーパス: mycophenolate mofetil

1 rrow infusion then steroids, tacrolimus, and mycophenolate mofetil.

2 e immunosuppression (IS) with tacrolimus and mycophenolate mofetil.

3 ts were randomized to methotrexate and 39 to mycophenolate mofetil.

4 n between patients receiving methotrexate or mycophenolate mofetil.

5 eiving calcineurin inhibitors, steroids, and mycophenolate mofetil.

6 erious effects of rapamycin, tacrolimus, and mycophenolate mofetil.

7 estimated GFR, male sex, and treatment with mycophenolate mofetil.

8 imen consisting of tacrolimus, steroids, and mycophenolate mofetil.

9 revented by immunosuppression with FK506 and mycophenolate mofetil.

10 pression, all dogs received cyclosporine and mycophenolate mofetil.

11 te globulin induction and were maintained on mycophenolate mofetil.

12 immunosuppression regimens of tacrolimus and mycophenolate mofetil.

13 graft recipients treated with tacrolimus and mycophenolate mofetil.

14 d post-HCT cyclophosphamide, tacrolimus, and mycophenolate mofetil.

15 B cells that persisted after treatment with mycophenolate mofetil.

16 d thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

17 the metabolism of the immunosuppressant drug mycophenolate mofetil.

18 ften in patients given cyclophosphamide than mycophenolate mofetil.

19 FK506 but can be blocked by the presence of mycophenolate mofetil.

20 (1.61 [1.11-2.34], P = 0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], P = 0.03).

21 n (1.61 [1.11-2.34], p=0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], p= 0.03).

22 ly for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28)

23 ive oral methotrexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followe

24 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclo

25 dnisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean o

26 , total body irradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte ser

27 on days 3 and 4 after transplantation, oral mycophenolate mofetil 15 mg/kg per dose (maximum 1 g) ev

28 itor-withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

29 , double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprin

30 Post grafting immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 day

31 ethotrexate, 25 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109).

32 preva Lupus Management Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment

33 ts were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

34 vents was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

35 or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%).

36 es (95% CI: 0.6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statist

37 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, a drug that is widely used for im

38 fidence interval [CI] 2.03-6.39), Neoral and mycophenolate mofetil (AHR 2.09, CI 1.31-3.31), and siro

39 (AHR 2.09, CI 1.31-3.31), and sirolimus and mycophenolate mofetil (AHR 2.77, CI 1.40-5.47), were ass

40 with patients treated with cyclosporine and mycophenolate mofetil alone.

41 g enteric-coated mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tac

42 nolic acid (MPA) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive dr

43 d prolonged-release tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative cort

44 16 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), wi

45 ly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

46 Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.

47 aCD20 antibody, followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40

48 Large controlled trials using mycophenolate mofetil and azathioprine for maintenance t

49 e that conventional immunomodulators such as mycophenolate mofetil and biologics such as rituximab ar

50 QD 0.3 mg/kg per day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over

51 regimens or placebo, both on a background of mycophenolate mofetil and corticosteroids.

52 2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 random

53 the % FVC improved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

54 her abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids.

55 All patients received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

56 nt and graft survivals after introduction of mycophenolate mofetil and induction with basiliximab.

57 was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide i

58 ts given CBMPs were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monot

59 e active immunosuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it i

60 ll case series suggest that a combination of mycophenolate mofetil and prednisone may be an effective

61 py with rabbit ATG, mycophenolate sodium, or mycophenolate mofetil and rapid withdrawal of steroids.

62 On the background of negative trials with mycophenolate mofetil and rituximab, there are recent da

63 low and even no oral steroids can be used in mycophenolate mofetil and rituximab-based regimes.

64 ave unexpected ALPS-specific toxicities, and mycophenolate mofetil and sirolimus have been demonstrat

65 d with 30% to 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

66 on and SF immunosuppression with maintenance mycophenolate mofetil and tacrolimus between October 200

67 ipeptidylpeptidase-deficient F344 rats using mycophenolate mofetil and tacrolimus for partial lymphoc

68 py with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the mo

69 Mycophenolate mofetil and TNF-alpha antagonists can be u

70 All patients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocortico

71 ly oral methotrexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 m

72 inhibitor (CNI) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in varia

73 I 1.09-2.93, compared with use of tacrolimus/mycophenolate mofetil) and following a diagnosis of cuta

74 nance with tacrolimus/cyclosporine (FK/CSA), mycophenolate mofetil, and a rapid steroid taper.

75 plored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone,

76 on and triple maintenance therapy (steroids, mycophenolate mofetil, and calcineurin inhibitor).

77 ession consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of pat

78 or induction in combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

79 All subjects received basiliximab induction, mycophenolate mofetil, and corticosteroids.

80 d tritherapy associating standard-dose CNIs, mycophenolate mofetil, and corticosteroids.

81 ion and maintenance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids.

82 RDP using thymoglobulin, mycophenolate mofetil, and CsA in selected pediatric KTx

83 sone tapered off over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

84 ter transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

85 emotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

86 t was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate.

87 ldren with SLE received cyclophosphamide and mycophenolate mofetil, and more children with JIA receiv

88 (90% CI 0.54-0.94; p=0.044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

89 thotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

90 (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

91 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

92 Tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

93 ere haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclopho

94 ppressive regime consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolera

95 ept or tacrolimus combined with basiliximab, mycophenolate mofetil, and prednisolone.

96 te globulin, methylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

97 d rabbit antithymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

98 se results, the combination of cyclosporine, mycophenolate mofetil, and sirolimus has become the new

99 iple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus).

100 GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus.

101 ntithymocyte globulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 a

102 ody induction followed by de novo sirolimus, mycophenolate mofetil, and steroids were compared; group

103 ion therapy, in combination with tacrolimus, mycophenolate mofetil, and steroids.

104 ndardized immunosuppression with tacrolimus, mycophenolate mofetil, and steroids.

105 tithymocyte globulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

106 an induction antibody followed by sirolimus, mycophenolate mofetil, and steroids.

107 ss costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI with

108 ttransplantation high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

109 ing, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

110 e group given basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus.

111 nance immunosuppression was with prednisone, mycophenolate mofetil, and tacrolimus.

112 tween the 2 groups consisting of prednisone, mycophenolate mofetil, and tacrolimus.

113 Methotrexate and mycophenolate mofetil are commonly used immunomodulatory

114 Both MPA and mycophenolate mofetil are highly specific inhibitors of

115 Calcineurin inhibitors and mycophenolate mofetil are potential salvage therapies, a

116 ting immunosuppression with cyclosporine and mycophenolate mofetil as a control group, we compared ou

117 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gu

118 Mycophenolate mofetil at intensified and individually ad

119 h enteric-coated mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans

120 deceased donor KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

121 eks, or tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids

122 lung disease, and the present preference for mycophenolate mofetil because of its better tolerability

123 ther reduced calcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switch

124 and immunosuppression regimes (azathioprine, mycophenolate mofetil, calcineurin inhibitors, mammalian

125 nation therapy with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphos

126 lonal antibody induction with tacrolimus and mycophenolate mofetil combination maintenance, both regi

127 dults with noninfectious uveitis, the use of mycophenolate mofetil compared with methotrexate as firs

128 A total of 67 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcom

129 ee immunosuppressive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interle

130 her a CNI-free regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interle

131 RL is most commonly used in combination with mycophenolate mofetil, CsA, or TAC.

132 SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from C

133 ence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.

134 Mycophenolate mofetil did not provide mycophenolic acid

135 Mycophenolate mofetil dose reduction was independently a

136 In the triple-drug group, mycophenolate mofetil doses were the same as in the stan

137 dose equal to or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly hig

138 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between gro

139 derma-related interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide fo

140 l effectiveness of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-relate

141 sitivity, hepatitis C virus reinfection, and mycophenolate mofetil-free regimens were significant ris

142 Relapses were more common in the mycophenolate mofetil group (42/76 patients) compared wi

143 ed from baseline to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88

144 e adverse events in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18

145 thioprine group and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of

146 ilure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the

147 y kidney transplant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g ent

148 Mycophenolate mofetil has emerged as a viable alternativ

149 Mycophenolate mofetil has not become the "wonder drug" t

150 ptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0

151 same conditioning regimen with sirolimus and mycophenolate mofetil immune suppression.

152 llowed by a short course of cyclosporine and mycophenolate mofetil immunosuppression.

153 olonged-release tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is effic

154 solimumab nonimprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunom

155 rmine whether rituximab with azathioprine or mycophenolate mofetil improves the high-resolution compu

156 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated singl

157 provement was observed in patients receiving mycophenolate mofetil in any treatment combination (HR 0

158 are recent data demonstrating superiority of mycophenolate mofetil in certain subgroups.

159 ted case reports of the use of rituximab and mycophenolate mofetil in resistant disease.

160 Mycophenolate mofetil is a potent immunosuppressant medi

161 l studies suggest that the immunosuppressant mycophenolate mofetil is associated with anemia.

162 hymocyte globulin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patie

163 ith interstitial lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis

164 tides (IMPROVE), to test the hypothesis that mycophenolate mofetil is more effective than azathioprin

165 Mycophenolate mofetil is, therefore, a suitable alternat

166 ntenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remiss

167 Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (targe

168 or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose c

169 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) among renal transplant recip

170 Mycophenolate mofetil (MMF) and combination therapies in

171 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), ar

172 acrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart tra

173 ceiving tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a re

174 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of

175 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficien

176 atical model using T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

177 id corticosteroid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month followed by rand

178 olimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host diseas

179 Clinicians are increasingly using mycophenolate mofetil (MMF) for the treatment of systemi

180 d with tacrolimus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individuall

181 calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine pract

182 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenan

183 r trial to determine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of ini

184 e evidence of favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, it

185 well as to characterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

186 ebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(

187 nzyme activity and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be geneticall

188 Mycophenolate mofetil (MMF) is an alternative to cycloph

189 Mycophenolate mofetil (MMF) is an immunosuppressive agen

190 The use of mycophenolate mofetil (MMF) is associated with less acut

191 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-

192 -coated mycophenolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) maintenance immunosuppressio

193 Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over in

194 ssigned 1:1 on day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with

195 -blinded trial, was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was sup

196 Mycophenolate mofetil (MMF) side effects often prompt do

197 st basiliximab induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplanta

198 el studies demonstrated that conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenol

199 Rodnan skin score (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

200 udy was to assess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blo

201 We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiograp

202 rd maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

203 to compare tacrolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus.

204 xamined the association of tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisone with BKN in

205 icularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

206 All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and p

207 rolled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticoster

208 rednisolone 2 mg/kg per day plus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denile

209 itor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF).

210 ines were treated with the immunosuppressant mycophenolate mofetil (MMF).

211 ng maintenance with both corticosteroids and mycophenolate mofetil (MMF).

212 eated with the combination of tacrolimus and mycophenolate mofetil (MMF).

213 event rates for EC-MPS were comparable with mycophenolate mofetil (MMF).

214 drug and a calcineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacroli

215 eived tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-

216 ip), tacrolimus (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or ve

217 ficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic a

218 idine, azaribine, pyrazofurin [PF], AVN-944, mycophenolate mofetil [MMF], and mycophenolic acid [MPA]

219 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the f

220 uding sirolimus (n = 5), bortezomib (n = 3), mycophenolate mofetil (n = 2), splenectomy (n = 2), and

221 ts were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for

222 42 patients were randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

223 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]

224 s), with an unadjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [

225 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

226 henolic acid (MPA), the active metabolite of mycophenolate mofetil, on erythropoiesis in vitro.

227 es immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with gluco

228 nts received systemic immunosuppression with mycophenolate mofetil or cyclosporine A.

229 had worsened gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac

230 were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.

231 The maintenance regimen of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associ

232 =0.003) than the regimen of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

233 Whether treatments such as mycophenolate mofetil or statins have a role in preventi

234 d GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination re

235 tment success with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

236 ), and higher mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

237 corticosteroids, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydro

238 antithymocyte globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28,

239 uded maintenance therapy with belatacept and mycophenolate mofetil plus induction with basiliximab an

240 loped stable graft function for >=2 years on mycophenolate mofetil plus prednisone.

241 adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with

242 unosuppressive protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte glo

243 pressive treatment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, a

244 ritis confirmed with biopsy and treated with mycophenolate mofetil presented with a 2-day history of

245 uccess in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients wit

246 g sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing

247 l randomized controlled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Va

248 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a

249 he addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of a

250 Adding sirolimus to cyclosporine and mycophenolate mofetil resulted in a significantly lower

251 temic sclerosis treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib,

252 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

253 , tacrolimus (FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (MMF).

254 lant or to continue standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids.

255 drawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTA

256 followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg thre

257 d to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after indu

258 d were discharged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

259 cipients maintained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

260 olimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/

261 were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of thes

262 s under antithymocyte globulin induction and mycophenolate mofetil-tacrolimus maintenance immunosuppr

263 l islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

264 oglobulin/interleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was em

265 mab induction was substituted with CBMPs and mycophenolate mofetil tapering was allowed.

266 ted for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intrav

267 mmy, centre-blocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily)

268 Fewer patients on mycophenolate mofetil than on cyclophosphamide premature

269 Combined prednisone and mycophenolate mofetil therapy is a potentially effective

270 Switching from mycophenolate mofetil to leflunomide successfully cleare

271 molluscum contagiosum who were switched from mycophenolate mofetil to leflunomide.

272 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to

273 e 5'-monophosphate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armament

274 for 2 weeks after each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

275 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) ce

276 either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid

277 Finally, delaying cyclosporine and mycophenolate mofetil until after MTX administration did

278 IS consisted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

279 while low DNAemia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral cap

280 d response system, stratified by concomitant mycophenolate mofetil use and presence or absence of int

281 acrolimus elimination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mo

282 Mycophenolate mofetil was associated with PCP risk only

283 Although mycophenolate mofetil was better tolerated and associate

284 standard GVHD prophylaxis group, 15 mg/kg of mycophenolate mofetil was given orally three times daily

285 Mycophenolate mofetil was initiated postoperatively with

286 Use of mycophenolate mofetil was inversely associated with vacc

287 Among patients with AAV, mycophenolate mofetil was less effective than azathiopri

288 , the addition of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a D

289 Mycophenolate mofetil was superior to azathioprine in ma

290 Mycophenolate mofetil was superior to azathioprine with

291 Mycophenolate mofetil was the treatment in 10 patients,

292 hen given in combination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonm

293 Thymoglobulin induction, tacrolimus, and mycophenolate mofetil were also associated.

294 Tacrolimus and mycophenolate mofetil were required as well as either ra

295 ab 1 month before transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery

296 A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunos

297 ession with oral tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the pre

298 enance immunosuppression with tacrolimus and mycophenolate mofetil with/without steroids.

299 mmunosuppression consisted of tacrolimus and mycophenolate mofetil without induction or depletional t

300 We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated,